Related Experiment Video
Updated: Mar 2, 2026
04:50
The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination
Published on: February 8, 2022
6.7K
Glycogenic Hepatopathy: Resolution with Minimal Glucose Control
Abhimanyu Chandel1, Brittany Scarpato1, Jeanette Camacho1
1Gastroenterology Department, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, USA.
Case Reports in Hepatology
|May 23, 2017
Summary
Glycogenic hepatopathy, a liver condition in poorly controlled type 1 diabetes, is often misdiagnosed. A liver biopsy confirmed the diagnosis, and symptoms improved with minor insulin adjustments.
Area of Science:
- Hepatology
- Endocrinology
- Diabetology
Background:
- Glycogenic hepatopathy is a rare complication of poorly controlled diabetes mellitus.
- It can mimic nonalcoholic fatty liver disease (NAFLD) on laboratory and imaging studies.
- Nonspecific symptoms often lead to diagnostic delays.
Observation:
- A case of glycogenic hepatopathy in a patient with type 1 diabetes is presented.
- The patient had poorly controlled diabetes with nonspecific symptoms.
- Initial laboratory and imaging findings were suggestive of NAFLD.
Findings:
- A liver biopsy was essential for diagnosing glycogenic hepatopathy.
- Characteristic pathological findings confirmed the diagnosis.
- The patient's symptoms resolved with minimal insulin regimen adjustments.
Implications:
- This case highlights the importance of considering glycogenic hepatopathy in diabetic patients with liver abnormalities.
- Early diagnosis and appropriate management can lead to symptom resolution.
- Further research is needed to differentiate glycogenic hepatopathy from NAFLD more effectively.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
687
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
687
01:23Dipeptidyl Peptidase 4 Inhibitors
787
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
787
01:30Acute Pancreatitis II: Clinical Manifestations and Management
975
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
975
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:22Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K